ArticleBiochemistry and biophysics reports2026
Ectopic endometrial mesenchymal stem cell-derived exosomal miR-4466 promotes angiogenesis by targeting RUNX1 in adenomyosis.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abnormal angiogenesis plays vital role in the pathogenesis of adenomyosis (AM). Emerging evidence suggests that exosomes derived from endometrial cells can accelerate the progression of AM. In this study, we aim to investigate the pro-angiogenic role and potential mechanisms of ectopic endometrial mesenchymal stem cells (eMSCs)-derived exosomes (Ec-exo). Methods: MicroRNA sequencing was conducted to identify differentially expressed miRNAs (DE-miRNAs) in exosomes derived from normal eMSCs (N-exo) and Ec-exo. Candidate miRNAs were selected using quantitative real-time polymerase chain reaction (qRT-PCR). The effects of miR-4466 on human umbilical vein endothelial cells (HUVECs) proliferation, invasion/migration, and tube formation were analysed in vitro. The target gene of miR-4466 was predicted via bioinformatics analysis and validated by qRT-PCR, western blotting, luciferase assays, and rescue experiments. Results: We identified 81 up-regulated and 92 down-regulated miRNAs between N-exo and Ec-exo. Among these DE-miRNAs, miR-4466 was the most significantly up-regulated. The internalisation assay demonstrated that exosomal miR-4466 can be internalised by HUVECs. Overexpression or inhibition of miR-4466 significantly promoted or inhibited HUVEC proliferation, invasion/migration, and tube formation. Bioinformatics predictions and luciferase assays revealed that runt-related transcription factor 1 (RUNX1) is a direct target of miR-4466. Moreover, rescue experiments confirmed that RUNX1 overexpression reversed the pro-angiogenic effect of miR-4466 by inhibiting vascular endothelial growth factor A (VEGFA) expression. Conclusions: Our study demonstrates that exosomal miR-4466 derived from ectopic eMSCs promotes angiogenesis by targeting the RUNX1/VEGFA axis in AM. These findings may offer new insights into therapeutic targets and treatment strategies for the anti-angiogenic treatment of AM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.